HC Wainwright Reaffirms Buy Rating for Genmab A/S (NASDAQ:GMAB)

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB - Free Report) in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a $50.00 price target on the stock.

Get Genmab A/S alerts:

A number of other analysts also recently commented on the stock. Royal Bank of Canada raised shares of Genmab A/S from a sector perform rating to an outperform rating in a report on Monday, July 15th. Morgan Stanley reaffirmed an equal weight rating and set a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. BTIG Research boosted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a buy rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Finally, Truist Financial reduced their price target on shares of Genmab A/S from $53.00 to $50.00 and set a buy rating on the stock in a research report on Monday, September 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $45.20.

View Our Latest Report on Genmab A/S

Genmab A/S Price Performance

GMAB stock traded down $0.90 during midday trading on Friday, hitting $25.58. 299,911 shares of the stock traded hands, compared to its average volume of 568,487. The firm has a market cap of $16.92 billion, a P/E ratio of 21.48, a PEG ratio of 0.81 and a beta of 0.99. The stock's fifty day simple moving average is $27.30 and its 200-day simple moving average is $28.01. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $37.00.

Ad Stansberry Research

New President Kamala warning

Financial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on her way to becoming the president of the United States. "Frankly, she scares us to death… and she should scare you," they wrote.

Which is why you need to check out their newest Kamala prediction immediately.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million for the quarter, compared to analysts' expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, research analysts predict that Genmab A/S will post 1.27 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. DDD Partners LLC purchased a new stake in Genmab A/S in the 2nd quarter valued at about $8,860,000. Capital International Investors lifted its position in Genmab A/S by 7.8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company's stock valued at $130,805,000 after purchasing an additional 315,355 shares during the last quarter. First Trust Advisors LP raised its holdings in shares of Genmab A/S by 16.0% during the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company's stock valued at $40,440,000 after acquiring an additional 175,292 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock worth $7,000,000 after purchasing an additional 145,689 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after buying an additional 103,859 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Should you invest $1,000 in Genmab A/S right now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report